AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27464467 — intervention group
Group type: EXPERIMENTAL
Intervention: Active e-cigarette smoking (smoked a pre-determined number of puffs within 30-min using a liquid with 11 ng/ml nicotine)
Number of subjects: 30
Study 27464467 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tobacco cigarette smoking (exposure of 1 h to 23 ± 1 ppm of CO in a 60 m³ environmental chamber)
Number of subjects: 30
Study 27464467 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive e-cigarette smoking (exposure of 1 h to air enriched with pre-determined number of puffs in a 60 m³ environmental chamber)
Number of subjects: 30
Study 27464467 — intervention group
Group type: COMPARATOR
Intervention: Control session for smokers
Number of subjects: 30
Study 27464467 — intervention group
Group type: COMPARATOR
Intervention: Control session for nonsmokers
Number of subjects: 30
Study 24906491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 106
Study 24906491 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 106
Study 24906491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 23299877 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response survey (IVRS)
Number of subjects: 0
Study 23299877 — intervention group
Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 0
Study 23299877 — intervention group
Group type: COMPARATOR
Intervention: Prior knowledge of biomarkers
Number of subjects: 0
Study 23299877 — intervention group
Group type: COMPARATOR
Intervention: Presence of semenogelin biomarker
Number of subjects: 0
Study 23299877 — intervention group
Group type: COMPARATOR
Intervention: Overall gel use
Number of subjects: 0
Study 20463641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 141
Study 20463641 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CsA)
Number of subjects: 141
Study 18368636 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual guaiac-based faecal occult blood test with three test cards for consecutive samples and colonoscopies offered to those with any blood observed.
Number of subjects: 52994
Study 18368636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving screening).
Number of subjects: 52994
Study 16816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support group
Number of subjects: 96
Study 16816305 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 96
Study 16816305 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 96
Study 12660312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.6 and 0.85 mg of DMT/kg of body weight)
Number of subjects: 18
Study 12660312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (high dose)
Number of subjects: 18
Study 12660312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (low and high doses)
Number of subjects: 18
Study 12660312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 18
Study 12660312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10661673 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale Adherence and Competence Scale (YACS)
Number of subjects: 0
Study 8862490 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist and menotropin therapy
Number of subjects: 63
Study 8862490 — intervention group
Group type: COMPARATOR
Intervention: GnRH analog alone
Number of subjects: 63
Study 1640854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI) at 25 ng/kg/min for 5.5 hours after a basal overnight insulin infusion (12 mU/kg/h)
Number of subjects: 7
Study 1640854 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI)
Number of subjects: 7
Study 29274158 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm laser (KTP)
Number of subjects: 20
Study 29274158 — intervention group
Group type: COMPARATOR
Intervention: diode laser 980 nm
Number of subjects: 20
Study 27809778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation with pectin (FMTP)
Number of subjects: 7
Study 27809778 — intervention group
Group type: COMPARATOR
Intervention: Fecal microbiota transplantation without pectin (FMT)
Number of subjects: 7
Study 25036218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige Cervical Disc
Number of subjects: 541
Study 25036218 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (Control)
Number of subjects: 541
Study 22700685 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation system (mECC), n = 10
Number of subjects: 20
Study 22700685 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation system (cECC), n = 10
Number of subjects: 20
Study 20841534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrifice reminders survey (n = 120)
Number of subjects: 301
Study 20841534 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested rationalization survey (n = 121)
Number of subjects: 301
Study 20841534 — intervention group
Group type: COMPARATOR
Intervention: Control survey (n = 60)
Number of subjects: 301
Study 18706202 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1 and 8 of a 21-day cycle)
Number of subjects: 100
Study 18706202 — intervention group
Group type: COMPARATOR
Intervention: 4-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1000 mg/m² on days 1, 8 and 15 of a 28-day cycle)
Number of subjects: 100
Study 16484895 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity method (SAPS II over the median)
Number of subjects: 12215
Study 16484895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-of-care method (>1 day of high level of care)
Number of subjects: 12215
Study 16484895 — intervention group
Group type: EXPERIMENTAL
Intervention: MIX method (both Severity and Intensity-of-care criteria)
Number of subjects: 12215
Study 16484895 — intervention group
Group type: COMPARATOR
Intervention: SAPS II model (unsplit sample)
Number of subjects: 12215
Study 12946549 — intervention group
Group type: EXPERIMENTAL
Intervention: Gengraf
Number of subjects: 1906
Study 12946549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine Capsule Satisfaction Survey
Number of subjects: 1906
Study 10701814 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional blood pressure (CBP) measurements at baseline and follow-up
Number of subjects: 692
Study 10701814 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure (ABP) monitoring at follow-up
Number of subjects: 692
Study 10701814 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cadmium concentration (B-Cd) and urinary cadmium excretion (U-Cd) measurements
Number of subjects: 692
Study 10701814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional analyses of CBP and ABP
Number of subjects: 692
Study 10701814 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of hypertension
Number of subjects: 692
Study 9269703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (mean arterial pressure of 92 mmHg)
Number of subjects: 0
Study 9269703 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure goal (mean arterial pressure of 107 mmHg)
Number of subjects: 0
Study 9269703 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 0
Study 8443032 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN; 20 mg orally)
Number of subjects: 12
Study 3535357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo‐Progynon (estradiol‐valerate and norgestrel)
Number of subjects: 30
Study 3535357 — intervention group
Group type: COMPARATOR
Intervention: EM 627 (estradiol and medroxy‐progesterone acetate)
Number of subjects: 30
Study 3535357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 27468086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) including aspirin plus clopidogrel 75 mg/d or prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years)
Number of subjects: 9101
Study 27468086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 9101
Study 24334689 — intervention group
Group type: EXPERIMENTAL
Intervention: CC‐JEV (17 μg per dose)
Number of subjects: 952
Study 24334689 — intervention group
Group type: EXPERIMENTAL
Intervention: CC‐JEV (4 μg per dose)
Number of subjects: 952
Study 24334689 — intervention group
Group type: EXPERIMENTAL
Intervention: CC‐JEV (8 μg per dose)
Number of subjects: 952
Study 24334689 — intervention group
Group type: COMPARATOR
Intervention: MB‐JEV (17 μg per dose)
Number of subjects: 952
Study 23221288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) model
Number of subjects: 0
Study 23221288 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized door-to-door survey
Number of subjects: 0
Study 23221288 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with community partner
Number of subjects: 0
Study 20536495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 1007
Study 20536495 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (up to 320 mg/day)
Number of subjects: 1007
Study 20536495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 1007
Study 20536495 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 1007
Study 18692876 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 100 mg at 9 pm for 1 month
Number of subjects: 80
Study 18692876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16002805 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1 mg lutein (n = 8)
Number of subjects: 19
Study 16002805 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.5 mg lutein (n = 8)
Number of subjects: 19
Study 16002805 — intervention group
Group type: COMPARATOR
Intervention: No lutein (n = 3; control group)
Number of subjects: 19
Study 12461759 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method (CAM)
Number of subjects: 81
Study 10369152 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational medication management training
Number of subjects: 156
Study 10369152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive psychotherapy
Number of subjects: 156
Study 10369152 — intervention group
Group type: EXPERIMENTAL
Intervention: Key‐person counseling
Number of subjects: 156
Study 10369152 — intervention group
Group type: COMPARATOR
Intervention: Structured free‐time activities
Number of subjects: 156
Study 7795913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 47
Study 7795913 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitors (SSRIs)
Number of subjects: 47
Study 7795913 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 47
Study 7795913 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 47
Study 7795913 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 47
Study 7795913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and fluvoxamine
Number of subjects: 47
Study 1781976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition enhancers (CEs) - piracetam, acetyl‐L‐carnitine, nimodipine (NIM)
Number of subjects: 100
Study 1781976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6783205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption (2 litres of tea daily, 4 bags of 2 g Assam/Ceylon tea per litre, steeped for 5 minutes)
Number of subjects: 12
Study 6783205 — intervention group
Group type: COMPARATOR
Intervention: Water consumption (2 litres of tap water daily)
Number of subjects: 12
Study 6783205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 12
Study 31575299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus usual care
Number of subjects: 88
Study 31575299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 31791431 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge approximation group (subgroup A)
Number of subjects: 120
Study 31791431 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge approximation group (subgroup B)
Number of subjects: 120
Study 31791431 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing group
Number of subjects: 120
Study 28004200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemia
Number of subjects: 518
Study 28004200 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin infusion
Number of subjects: 518
Study 26108255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx® (intact)
Number of subjects: 38
Study 26108255 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx® (crushed)
Number of subjects: 38
Study 26108255 — intervention group
Group type: COMPARATOR
Intervention: OxyContin® (crushed)
Number of subjects: 38
Study 26108255 — intervention group
Group type: COMPARATOR
Intervention: OxyContin® (intact)
Number of subjects: 38
Study 26108255 — intervention group
Group type: COMPARATOR
Intervention: IR oxycodone (crushed)
Number of subjects: 38
Study 23293276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of ropivacaine 1% (3 ml) before surgical dissection and normal saline 3 ml at the end of surgery (preoperative nebulization group)
Number of subjects: 3
Study 23293276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and ropivacaine 1% (3 ml) at the end of surgery (postoperative nebulization group)
Number of subjects: 3
Study 23293276 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and at the end of surgery (placebo group)
Number of subjects: 3
Study 21524172 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 302
Study 21524172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Conservative Treatment (UCT)
Number of subjects: 302
Study 21524172 — intervention group
Group type: COMPARATOR
Intervention: Conventional Restorative Treatment (CRT)
Number of subjects: 302
Study 21524172 — intervention group
Group type: EXPERIMENTAL
Intervention: FIS Tx-1 score
Number of subjects: 302
Study 19376305 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1400
Study 19376305 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1400
Study 19376305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy for 6 months
Number of subjects: 1400
Study 19376305 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy for 12 months
Number of subjects: 1400
Study 17214931 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Pingchuan Granule
Number of subjects: 80
Study 17214931 — intervention group
Group type: COMPARATOR
Intervention: Ruyi Dingchuan Pill
Number of subjects: 80
Study 12747505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rendering confidence judgments during the sensory discrimination task
Number of subjects: 0
Study 12747505 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken to render the judgment of confidence
Number of subjects: 0
Study 10960437 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (n = 105)
Number of subjects: 219
Study 10960437 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (n = 114)
Number of subjects: 219
Study 10960437 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 219
Study 10960437 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 219
Study 10960437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 219
Study 8637999 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 17
Study 8637999 — intervention group
Group type: COMPARATOR
Intervention: MIBG scintigraphy
Number of subjects: 17
Study 1592277 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, median survival time 19 months, estimated 7-year survival 12.2% (confidence limits 6.9-17.4)
Number of subjects: 529
Study 1592277 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and cyclophosphamide (CP), median survival time 20 months, estimated 7-year survival 17.0% (confidence limits 11.0-22.9)
Number of subjects: 529
Study 1592277 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, cyclophosphamide, and adriamycin (CAP), median survival time 23 months, estimated 7-year survival 21.7% (confidence limits 14.9-28.4)
Number of subjects: 529
Study 4015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (4 g intravenously every 12 h)
Number of subjects: 14
Study 4015075 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin (4 g intravenously every 12 h)
Number of subjects: 14
Study 30469412 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g/day)
Number of subjects: 34
Study 30469412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study 26521754 — intervention group
Group type: COMPARATOR
Intervention: SocketKAP(™)
Number of subjects: 36
Study 26521754 — intervention group
Group type: COMPARATOR
Intervention: SocketKAP(™) + ABBM
Number of subjects: 36
Study 26521754 — intervention group
Group type: COMPARATOR
Intervention: SocketKAP(™) + SocketKAGE(™) + ABBM
Number of subjects: 36
Study 26521754 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 36
Study 25132576 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 43
Study 25132576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 25132576 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress
Number of subjects: 43
Study 25132576 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 43
Study 22908103 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrient (MMN) supplementation during pregnancy and until 3 months postpartum
Number of subjects: 487
Study 22908103 — intervention group
Group type: COMPARATOR
Intervention: Maternal multiple micronutrient (MMN) supplementation
Number of subjects: 487
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed and totally hyaluronan based heparin free coated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed and totally uncoated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Open, totally hyaluronan based heparin free coated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: COMPARATOR
Intervention: Control - open, uncoated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed + coated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: Open + coated ECC
Number of subjects: 48
Study 21313926 — intervention group
Group type: EXPERIMENTAL
Intervention: All study groups
Number of subjects: 48
Study 17883016 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-and-packets group
Number of subjects: 0
Study 17883016 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-only group
Number of subjects: 0
Study 17883016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (both training-and-packets and training-only)
Number of subjects: 0
Study 17883016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16062093 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U botulinum toxin injected into the region of the zygomatic arch
Number of subjects: 8
Study 12161496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography/mass spectrometry method for simultaneous measurement of 15 urinary steroid metabolites
Number of subjects: 90
Study 12161496 — intervention group
Group type: COMPARATOR
Intervention: Gas chromatography/mass spectrometry method
Number of subjects: 90
Study 10341861 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha + iodine (10 drops SSKI, approximately 350 mg iodine daily)
Number of subjects: 48
Study 10341861 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine alone (10 drops SSKI, approximately 350 mg iodine daily)
Number of subjects: 48
Study 10341861 — intervention group
Group type: COMPARATOR
Intervention: rIFN-alpha alone
Number of subjects: 48
Study 10341861 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha + iodine
Number of subjects: 48
Study 10341861 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine alone
Number of subjects: 48
Study 7581061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 26
Study 2137472 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge in panic disorder patients
Number of subjects: 23
Study 2137472 — intervention group
Group type: COMPARATOR
Intervention: 35% CO2 challenge in healthy controls
Number of subjects: 23
Study 2137472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation provocation test in panic disorder patients
Number of subjects: 23
Study 2137472 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation provocation test in healthy controls
Number of subjects: 23
Study 6997111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release form of amitriptyline (Lentizol) 50 mg (doubled after 1 week)
Number of subjects: 50
Study 6997111 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin (Prothiaden) 75 mg (doubled after 1 week)
Number of subjects: 50
Study 31782643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 54
Study 31782643 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 54
Study 28391657 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg b.i.d.
Number of subjects: 254
Study 28391657 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg b.i.d.
Number of subjects: 254
Study 28391657 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 254